{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:32Z","timestamp":1786985432116,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bmcl.2025.130208","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:50:49Z","timestamp":1742863849000},"page":"130208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["PEG-ASO conjugates for efficient targeted delivery and migration inhibition in Cancer cell"],"prefix":"10.1016","volume":"122","author":[{"given":"Chunhui","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130208_bb0005","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","article-title":"Metastasis","volume":"186","author":"Gerstberger","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2025.130208_bb0010","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.add9667","article-title":"Engineering bacteria as interactive cancer therapies","volume":"378","author":"Gurbatri","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130208_bb0015","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmcl.2025.130208_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114872","article-title":"Development of nucleic acid medicines based on chemical technology","volume":"199","author":"Kawamoto","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmcl.2025.130208_bb0025","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/acs.bioconjchem.3c00205","article-title":"Ongoing clinical trials of nonviral siRNA therapeutics","volume":"34","author":"Narasipura","year":"2023","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmcl.2025.130208_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101634","article-title":"Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: a systematic review","volume":"31","author":"Ito","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.bmcl.2025.130208_bb0035","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmcl.2025.130208_bb0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2023.12.035","article-title":"Enabling safer, more potent oligonucleotide therapeutics with bottlebrush polymer conjugates","volume":"366","author":"Chen","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.bmcl.2025.130208_bb0045","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jconrel.2022.10.050","article-title":"Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics","volume":"352","author":"Ramasamy","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.bmcl.2025.130208_bb0050","doi-asserted-by":"crossref","first-page":"2100478","DOI":"10.1002\/adfm.202100478","article-title":"iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasis","volume":"31","author":"Guan","year":"2021","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.bmcl.2025.130208_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130208_bb0060","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1021\/acsnano.2c11675","article-title":"Aptamer nanoconstructs crossing human blood\u2013brain barrier discovered via microphysiological system-based SELEX technology","volume":"17","author":"Choi","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.bmcl.2025.130208_bb0065","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","article-title":"Recent progress of aptamer\u2013drug conjugates in cancer therapy","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2025.130208_bb0070","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12951-023-01941-z","article-title":"Aptamer functionalized nucleic acid nano drug for targeted synergistic therapy for colon cancer","volume":"21","author":"Zhu","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.bmcl.2025.130208_bb0075","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2025.130208_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130208_bb0085","article-title":"Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides","volume":"119","author":"Wang","year":"2022","journal-title":"P Natl Acad Sci"},{"key":"10.1016\/j.bmcl.2025.130208_bb0090","article-title":"Synthesis and biophysical properties of tetravalent PEG-conjugated antisense oligonucleotide","volume":"78","author":"Rahman","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2025.130208_bb0095","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers","volume":"10","author":"Skog","year":"2008","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.bmcl.2025.130208_bb0100","article-title":"The role of microRNA-21 (miR-21) in pathogenesis, diagnosis, and prognosis of gastrointestinal cancers: a review","volume":"316","author":"Farasati","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.bmcl.2025.130208_bb0105","doi-asserted-by":"crossref","first-page":"ra75","DOI":"10.1126\/scisignal.2001868","article-title":"Signaling by the matrix proteoglycan Decorin controls inflammation and Cancer through PDCD4 and MicroRNA-21","volume":"4","author":"Merline","year":"2011","journal-title":"Sci Signal"},{"key":"10.1016\/j.bmcl.2025.130208_bb0110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1039\/C9TX00019D","article-title":"MiRNA-21 functions in ionizing radiation-induced epithelium-to-mesenchymal transition (EMT) by downregulating PTEN","volume":"8","author":"Liu","year":"2019","journal-title":"Toxicol Res"},{"key":"10.1016\/j.bmcl.2025.130208_bb0115","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1021\/acs.bioconjchem.2c00144","article-title":"Preparation of maleimide-modified oligonucleotides from the corresponding amines using N-methoxycarbonylmaleimide","volume":"33","author":"Kj\u00e6rsgaard","year":"2022","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmcl.2025.130208_bb0120","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41557-018-0209-2","article-title":"Maleimide\u2013thiol adducts stabilized through stretching","volume":"11","author":"Huang","year":"2019","journal-title":"Nat Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T01:48:07Z","timestamp":1744336087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":24,"alternative-id":["S0960894X25001179"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130208","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PEG-ASO conjugates for efficient targeted delivery and migration inhibition in Cancer cell","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130208"}}